<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00874146</url>
  </required_header>
  <id_info>
    <org_study_id>ONC/OSS-03-2008</org_study_id>
    <nct_id>NCT00874146</nct_id>
  </id_info>
  <brief_title>Level of HER2-neu Gene Amplification an Response to Trastuzumab</brief_title>
  <official_title>Retrospective Study of the Level of HER2-neu Gene Amplification as Predictive Factor of Response in Patients With HER2-positive Advanced Breast Cancer Treated With Trastuzumab Containing Regimens.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective of the study is to evaluate the correlation between level of HER2-neu gene
      amplification evalued by dual-color Fluorescent in-situ hybridization (FISH) test and time to
      progression (TTP) in patients with HER2-positive advanced breast cancer treated with
      trastuzumab-containing regimens.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Association of tumor cytogenetic paremeters with TTP and OS.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Association of cytogenetic parameters evalued by FISH test and patients' characteristics.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>HER2-positive advanced breast cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Fluorescent in-situ hybridization (FISH)</intervention_name>
    <description>Dual color FISH test to assess ratio of HER2/neu amplification</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      FISH test performed on paraffine embedded tumor sections.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HER2-positive advanced breast cancer treated with trastuzumab-containing
        regimen.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HER2-positive breast cancer Trastuzumab-containing regimen delivered for advanced
             disease Tumor sample available at Pathology Archive

        Exclusion Criteria:

          -  HER2-negative advanced breast cancer Pretreatment with trastuzumab
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armando Santoro, MD</last_name>
    <phone>++39-028224</phone>
    <phone_ext>4080</phone_ext>
    <email>armando.santoro@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe Gullo, MD</last_name>
    <phone>++39-028224</phone>
    <phone_ext>4080</phone_ext>
    <email>giuseppe.gullo@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinco Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milan</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
      <phone>+39028224</phone>
      <phone_ext>4080</phone_ext>
      <email>armando.santoro@humanitas.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe Gullo, MD</last_name>
      <phone>+39028224</phone>
      <phone_ext>4080</phone_ext>
      <email>giuseppe.gullo@humanitas.it</email>
    </contact_backup>
    <investigator>
      <last_name>Giuseppe Gullo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2009</study_first_submitted>
  <study_first_submitted_qc>April 1, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2009</study_first_posted>
  <last_update_submitted>September 1, 2010</last_update_submitted>
  <last_update_submitted_qc>September 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Armando Santoro, MD</name_title>
    <organization>Istituto Clinico Humanitas</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

